1. Home
  2. BTDR vs TSHA Comparison

BTDR vs TSHA Comparison

Compare BTDR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bitdeer Technologies Group

BTDR

Bitdeer Technologies Group

N/A

Current Price

$5.67

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

N/A

Current Price

$4.12

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTDR
TSHA
Founded
2021
2019
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BTDR
TSHA
Price
$5.67
$4.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
13
Target Price
★ $20.92
$13.00
AVG Volume (30 Days)
★ 10.1M
3.2M
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 5.56
EPS
★ N/A
N/A
Revenue
N/A
★ $9,773,000.00
Revenue This Year
$54.56
N/A
Revenue Next Year
$70.16
$783.47
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 17.28
52 Week Low
$5.03
$3.46
52 Week High
$20.72
$7.30

Technical Indicators

Market Signals
Indicator
BTDR
TSHA
Relative Strength Index (RSI) 36.09 43.88
Support Level $5.03 $3.92
Resistance Level $13.15 $4.59
Average True Range (ATR) 0.73 0.29
MACD 0.05 0.04
Stochastic Oscillator 19.28 24.59

Price Performance

Historical Comparison
BTDR
TSHA

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: